NLNK - NewLink Genetics Corporation
| Previous Close | 1.9900 |
| Open | 1.9900 |
| Bid | 2.0400 x 2200 |
| Ask | 2.0600 x 800 |
| Day's Range | 1.9325 - 2.0800 |
| 52 Week Range | 1.1300 - 3.6000 |
| Volume | 682,356 |
| Avg. Volume | 1,100,065 |
| Market Cap | 76.121M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2150 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Benzinga
The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
- GlobeNewswire
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
NewLink Genetics Corporation (NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited (Ellipses) for the development of and rights to commercialize NLG207 (formerly CRLX101), a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin. This license agreement signed by NewLink Genetics and Ellipses is effective as of December 17, 2019. Under the terms of the agreement, Ellipses purchased NewLink’s inventory of NLG207 related materials, and NewLink will have the potential to receive future royalty payments or a share of any future economics related to NLG207.
- Insider Monkey
Is NewLink Genetics Corp (NLNK) A Good Stock To Buy?
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
- GlobeNewswire
NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)
NewLink Genetics Corporation (NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (MRK), known as MSD outside the US and Canada. This represents the first vaccine approved by the FDA for the Ebola virus and follows the November 11th grant by the European Commission (EC) of a marketing authorization for ERVEBO® across 31 European countries. Yesterday’s approval comes almost three months prior to the Prescription Drug User Fee Act (PDUFA), or target FDA action date, originally set for March 14, 2020.
- Zacks
Do Options Traders Know Something About NewLink Genetics (NLNK) Stock We Don't?
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
- GlobeNewswire
NewLink Genetics Responds to Proposal from Evercel
The NewLink Board of Directors (the “Board”), consistent with its fiduciary duties and in consultation with outside financial and legal advisors, thoroughly evaluated the Evercel proposal and has determined that it is not in the best interests of NewLink’s stockholders. The Board concluded that the Evercel proposal is not actionable because it does not constitute, and could not reasonably be expected to lead to, a “Superior Offer” as defined in the definitive merger agreement (the “Lumos Merger Agreement”) with Lumos Pharma, Inc. (“Lumos”).
- Benzinga
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...
- GlobeNewswire
Evercel Announces Rejected Offer to Acquire NewLink Genetics
Evercel, Inc. (“Evercel”) (EVRC) has made an offer to acquire NewLink Genetics Corporation ("NewLink") (NLNK). Daniel Allen, Chief Executive Officer of Evercel, announced on November 25, 2019 Evercel has made alternative offers to acquire NewLink, including one for $1.75 in cash per share.
- Thomson Reuters StreetEvents
Edited Transcript of NLNK earnings conference call or presentation 6-Nov-19 1:30pm GMT
Q3 2019 NewLink Genetics Corp Earnings Call
- GlobeNewswire
NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
NewLink Genetics Corporation (NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO®, investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (MRK), known as MSD outside the US and Canada. With this approval, the EC will grant a centralized marketing authorization for the vaccine with unified labeling that is valid in 31 European countries. The granting of this approval by the EC follows the September 17th announcement by the FDA that it has accepted the Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920).
- GlobeNewswire
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
AMES, Iowa, Nov. 06, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update.
- GlobeNewswire
NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019
The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/mmc/p/sm3cyp39. NewLink Genetics is a clinical stage biopharmaceutical company that has been focused on novel oncology product candidates targeting indications with limited treatment options. On September 30, 2019, NewLink announced its intent to merge with Lumos Pharma, a private clinical-stage biopharmaceutical company targeting rare and neglected diseases.
- Benzinga
The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
- GlobeNewswire
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)
NewLink Genetics Corporation (NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing authorization for investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck & Co., Inc. (MRK). This Committee recommendation will now be reviewed by the European Commission (EC) which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine (brand name ERVEBO®) under a unified label valid in 31 European countries. Should this vaccine be approved by the FDA, a monetizable Priority Review Voucher (PRV) would be issued, in which NewLink Genetics owns a substantial financial interest.
- Benzinga
The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE/Nasdaq-listed biotech stocks hit 52-week highs on Oct. 1. Down In The Dumps (Biotech stocks hitting 52-week ...
- Benzinga
The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
- GlobeNewswire
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
NewLink Genetics Corporation (NLNK) and Lumos Pharma, Inc., a private clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare diseases, today announced that the companies have entered into a definitive merger agreement. Under the terms of the agreement, NewLink will issue Lumos Pharma stockholders NewLink common stock in exchange for their shares in Lumos such that Lumos Pharma stockholders will own approximately 50% of NewLink.
- Benzinga
NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status
Potential approval of the vaccine will trigger issuance of a priority review voucher owned by Merck and in which NewLink has a substantial economic interest. The priority review voucher program was created by the U.S. Congress in 2007, and under the program, on approval of a treatment for a neglected or rare pediatric disease, the developer will be issued a voucher for priority review for a different drug as a means of incentivizing development of treatments for neglected and rare diseases. "We are pleased with this morning's announcement from our partner, Merck.
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
- GlobeNewswire
NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)
NewLink Genetics Corporation (NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the prevention of disease caused by the Ebola Zaire virus. Merck’s rolling submission was made pursuant to the FDA’s Breakthrough Therapy Designation for V920, a designation awarded to our partner, Merck, in July 2016. As NewLink has previously stated, the FDA’s approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.
- Zacks
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock?
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
- Simply Wall St.
Could NewLink Genetics Corporation's (NASDAQ:NLNK) Investor Composition Influence The Stock Price?
Every investor in NewLink Genetics Corporation (NASDAQ:NLNK) should be aware of the most powerful shareholder groups...
